Search results
Results from the WOW.Com Content Network
Allergic bronchopulmonary aspergillosis; Other names: ABPA, Hinson-Pepys disease. The chest radiograph of an allergic bronchopulmonary aspergillosis patient shown with left-sided perihilar opacity (blue arrow) along with non-homogeneous infiltrates (transient pulmonary infiltrates indicated by red arrows) in all zones of both lung fields.
The mechanism of action of itraconazole is the same as the other azole antifungals: it inhibits the fungal-mediated synthesis of ergosterol, via inhibition of lanosterol 14α-demethylase. Because of its ability to inhibit cytochrome P450 3A4 CC-3, caution should be used when considering interactions with other medications.
A rapidly invasive Aspergillus infection in the lungs often causes cough, fever, chest pain, and difficulty breathing. [citation needed] Poorly controlled aspergillosis can disseminate through the blood to cause widespread organ damage. [2] Symptoms include fever, chills, shock, delirium, seizures, and blood clots.
Voriconazole, sold under the brand name Vfend among others, is an antifungal medication used to treat a number of fungal infections. [5] This includes aspergillosis, candidiasis, coccidioidomycosis, histoplasmosis, penicilliosis, and infections by Scedosporium or Fusarium. [5] It can be taken by mouth or used by injection into a vein. [5]
Fungal pneumonia is an infection of the lungs by fungi. It can be caused by either endemic or opportunistic fungi or a combination of both. Case mortality in fungal pneumonias can be as high as 90% in immunocompromised patients, [ 1 ] [ 2 ] though immunocompetent patients generally respond well to anti-fungal therapy.
However, itraconazole seems to perform better in skeletal lesions, whereas fluconazole performs better in pulmonary and soft tissue infection. Serum levels of itraconazole are commonly obtained at the onset of long-term therapy because its absorption is sometimes erratic and unpredictable. Complications can include hepatic dysfunction.
Itraconazole (R51211), invented in 1984, is a triazole fungistatic antifungal agent prescribed to patients with fungal infections. The drug may be given orally or intravenously. Itraconazole has a broader spectrum of activity than fluconazole (but not as broad as voriconazole or posaconazole).
Esophageal candidiasis is an opportunistic infection of the esophagus by Candida albicans. The disease usually occurs in patients in immunocompromised states, including post-chemotherapy and in AIDS. However, it can also occur in patients with no predisposing risk factors, and is more likely to be asymptomatic in those patients. [1]